Drug resistant mutations detected by genotypic drug resistance testing in patients failing therapy in clade C HIV-1 infected individuals from India

Indian Journal of Medical Microbiology

Volumn 27, Issue 3, 2009, Pages 231-236

  Kandathil, A J ^a   Kannangai, R ^a   Verghese, V P ^b   Pulimood, S A ^a   Rupali, P ^a   Sridharan, G ^a   Grant, P ^c   Pillay, D ^c   Abraham, O C ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Departments of Child Health

^c CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

Clade C; Drug resistance; HIV 1; India; Treatment failure

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; BLOOD SAMPLING; CLADISTICS; CONTROLLED STUDY; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INDIA; MULTIDRUG RESISTANCE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRACTICE GUIDELINE; PREVALENCE; QUALITY CONTROL; SEQUENCE ANALYSIS; TREATMENT FAILURE; VIRUS LOAD; VIRUS STRAIN;

EID: 67749084743     PISSN: 02550857     EISSN: 19983646     Source Type: Journal    
DOI: 10.4103/0255-0857.53205     Document Type: Article

References (20)

1. Nischal KC, Khopkar U, Saple DG. Improving adherence to antiretroviral therapy. Indian J Dermatol Venereol Leprol 2005;71:316-20.
2. Carrieri P, Cailleton V, Le Moing V, Spire B, Dellamonica P, Bouvet E, et al. The dynamic of adherence to highly active antiretroviral therapy: results from the French National APROCO cohort. J Acquir Immune Defc Syndr 2001;28:232-9.
3. Clavel F, Hance AJ. HIV drug resistance. N Engl J Med 2004;350:1023-35.
4. Deshpande A, Jauvin V, Magnin N, Pinson P, Faure M, Masquelier B, et al. Resistance mutations in subtype C HIV type 1 isolates from Indian patients of Mumbai receiving NRTIs plus NNRTIs and experiencing a treatment failure: resistance to AR. AIDS Res Hum Retroviruses 2007;23:335-40.
5. Sen S, Tripathy SP, Chimanpure VM, Patil AA, Bagul RD, Paranjape RS. Human immunodefciency virus type 1 drug resistance mutations in peripheral blood mononuclear cell proviral DNA among antiretroviral treatment-naive and treatment-experienced patients from Pune, India. AIDS Res Hum Retroviruses 2007;23:489-97.
6. Kandathil AJ, Kannangai R, David S, Nithyanandam G, Solomon S, Balakrishnan P, et al. Comparison of Microcapillary Cytometry Technology and Flow Cytometry for CD4+ and CD8+ T-Cell Estimation. Clin Diagn Lab Immunol 2005;12:1006-9.
7. Kannangai R, Kandathil AJ, Ebenezer DL, Nithyanandam G, Samuel P, Abraham OC, et al. Evidence for lower CD4+ T cell and higher viral load in asymptomatic HIV-1 infected individuals of India (south): Implications for therapy initiation. Indian J Med Microbiol 2008;26:217-21.
8. Kandathil AJ, Kannangai R, Abraham OC, Priscilla R, Pulimood SA, Verghese VP, et al. The frequency of HIV-I drug resistance mutations among treatment naïve individuals at a tertiary care centre in south India. Int J STD and AIDS-(in press)
9. Tamura K, Dudley J, Nei M, Kumar S. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 2007;24:1596-9.
10. de Oliveira T, Deforche K, Cassol S, Salminen M, Paraskevis D, Seebregts C, et al. An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 2005;21:3797-800.
11. Geretti AM. Clinical implications of HIV drug resistance to nucleoside and nucleotide reverse transcriptase inhibitors. AIDS Rev 2006;8:210-20.
12. Shafer RW. Genotypic testing for human immunodefciency virus type 1 drug resistance. Clin Microbiol Rev 2002;15:247-77.
13. Van Vaerenbergh K, Van Laethem K, Albert J, Boucher CA, Clotet B, Floridia M, et al. Prevalence and characteristics of multinucleoside- resistant human immunodefciency virus type 1 among European patients receiving combinations of nucleoside analogues. Antimicrob Agents Chemother 2000;44:2109-17.
14. Coakley EP, Gillis JM, Hammer SM. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine. AIDS 2000;14:F9-15.
15. Lall M, Gupta RM, Sen S, Kapila K, Tripathy SP, Paranjape RS. Profle of primary resistance in HIV-1-infected treatment-naive individuals from Western India. AIDS Res Hum Retroviruses 2008;24:987-90.
16. Shao W, Everitt L, Manchester M, Loeb DD, Hutchison CA 3rd, Swanstrom R. Sequence requirements of the HIV-1 protease fap region determined by saturation mutagenesis and kinetic analysis of fap mutants. Proc Natl Acad Sci U S A 1997;94:2243-8.
17. Martinez-Cajas JL, Wainberg MA. Protease inhibitor resistance in HIV-infected patients: Molecular and clinical perspectives. Antiviral Res 2007;76:203-21.
18. Sen S, Tripathy SP, Patil AA, Chimanpure VM, Paranjape RS. High prevalence of human immunodefciency virus type 1 drug resistance mutations in antiretroviral treatment-experienced patients from Pune, India. AIDS Res Hum Retroviruses 2007;23:1303-8.
19. Kandathil AJ, Kannangai R, Abraham OC, Sudarsanam TD, Pulimood SA, Sridharan G. Genotypic resistance profle of HIV-1 protease gene: A preliminary report from Vellore, south India. Indian J Med Microbiol 2008;26:151-4.
20. Kandathil AJ, Ramalingam S, Kannangai R, David S, Sridharan G. Molecular epidemiology of HIV. Indian J Med Res 2005;121:333-44.